Resetting the Immune System

A new combination of immunotoxins targeting, in first place, Graft versus Host Disease, and useful for resetting the immune system in transplantees. This product for wich Henogen has the full IP, is expected to outperform existing immunotoxins in view of its lower toxicity and increased efficacity via synergic effects of active components.

Henogen's objectives cover the full scale development up to phase III clinical trial, production and distribution for the GvHD indication. In view of the wider therapeutical potential of these immunotoxins, Henogen expects to out-license their use for larger market indications.

Henogen’s product : A new combination of Immunotoxins MabCD3-dgA & CD7-dgA

• Multiple mechanisms (mAb/dgA)
• Cell kill through apoptosis (no cytokine release syndrome)
• Synergistic activity
• Dilution of toxicity (no vascular leak syndrome)